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Abstract
Background: Tissue inhibitors of metalloproteinases (TIMPs) play a key role in tissue degradation and remodeling. Since
chronic inflammation is associated with tissue remodeling in inflammatory bowel disease (IBD), we evaluated serum TIMP-1 and
TIMP-4 levels in IBD patients, in comparison with healthy controls (HC).
Methods: TIMP-1, TIMP-2 and TIMP-4 serum levels were determined in 53 patients with ulcerative colitis (UC), 52 patients
with Crohn's disease (CD) and 50 HC, by means of commercially available enzyme-linked immunosorbent assays. The levels of
TIMPs were evaluated with regard to the levels of inflammatory markers, such as C reactive protein (CRP) and serum amyloid
A (SAA) and the clinical characteristics of patients, so that potential correlations could be recorded.
Results: Mean serum TIMP-1 levels were 414.9 ± 17.6 ng/mL in UC patients, 446.1 ± 22.8 ng/mL in CD patients and 296.5 ±
20.6 ng/mL in HC. UC and CD patients had significantly higher serum TIMP-1 levels when compared to HC, (p < 0.0001 in both
groups). Mean serum TIMP-1 levels were significantly higher in patients with active IBD (450.5 ng/mL) in comparison with
patients with inactive disease (417.3 ng/mL, p = 0.03). Moreover, males showed significantly higher mean serum TIMP-1 levels
(399.8 ng/mL), compared to females (368.5 ng/mL, p = 0.04). Mean serum TIMP-2 levels did not differ between UC and CD
patients or HC (p > 0.05 in all cases). Mean serum TIMP-4 levels were 1761.2 ± 67.7 pg/mL in UC patients, 1708.1 ± 73.4 pg/
mL in CD patients and 5573.4 ± 1246.3 pg/mL in HC. UC and CD patients had significantly lower serum TIMP-4 levels when
compared to HC (p = 0.008 and p = 0.02 respectively). Mean serum TIMP-4 levels were significantly lower in males (2772.9 pg/
mL), compared to females (3299.0 pg/mL, p = 0.01). In addition, CRP levels showed a statistically significant correlation with
TIMP-1 (r = 0.247, p = 0.01), and TIMP-4 levels (r = 0.217, p = 0.03). Similarly, there was a statistically significant correlation
between SAA levels and both TIMP-1 (r = 0.264, p = 0.008) and TIMP-4 serum levels (r = 0.212, p = 0.03).
Conclusion: An imbalance between TIMP-1 and TIMP-4 serum levels is present in IBD patients. TIMP-1 levels could be used
not only for diagnostic purposes but also for the assessment of activity in IBD. Gender tends to influence TIMP-1 and TIMP-4
serum levels. These new findings bring into question the potential role of TIMPs in IBD, thus underlining the need for future
studies which could offer new insight into this matter.
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Background
Inflammatory bowel diseases (IBD), are characterized by
an inflammatory cascade of mediators capable of degrad-
ing and modifying bowel wall structure as well as induc-
ing the formation of chronic inflammatory lesions of the
digestive tract. The inflammatory cell infiltrate observed
in chronic mucosal inflammation is associated with
changes in epithelial proliferation and migration and
accompanied by intensive remodeling of the subepithelial
connective tissue, which in turn leads to increased turno-
ver of extracellular matrix (ECM) components [1,2]. A dis-
turbance in the balance between synthesis and
degradation of ECM components can result either in pro-
gressive organ destruction, as seen in ulcer formation, or
fibrosis due to excessive deposition of collagen [1,2].
Metalloproteinases (MMPs) and tissue inhibitors of met-
alloproteinases (TIMPs) show a regulated and coordi-
nated pattern of activity which allows tissue degradation
and remodeling but at the same time it prevents tissue
damage [3,4]. TIMPs are the natural inhibitors of MMPs
found in most tissues and body fluids. Currently, four
TIMPs (TIMP-1, -2, -3 and -4) are identified. Like MMPs,
the expression of TIMPs in the tissue is also controlled to
maintain a balance in the metabolism of the ECM [4].
Disruption of this balance may result in a number of path-
ogenic processes. The 21–34 kDa proteinic molecules of
TIMPs express an inhibitory activity which is facilitated by
their ability to form high-affinity non-covalent complexes
with the carboxyl-terminal domains of pro-MMPs [3].
TIMP-1, TIMP-2 and TIMP-4 are present in soluble forms,
while TIMP-3 is tightly bound to the matrix [4]. Numer-
ous studies have indicated that, independently of MMP
inhibition, TIMPs are multifunctional proteins involved
not only in tissue remodeling and wound healing but also
in many other physiological and pathological processes
such as angiogenesis, steroidogenesis, hematopoiesis, cell
growth and cell survival [4].
The TIMP-1 levels in the mucosa and plasma of IBD
patients have been shown to be elevated, in previous stud-
ies [5-8]. Moreover, the TIMP-1 plasma levels demon-
strate a significant positive correlation with the
endoscopic degree of mucosa injury, disease activity and
C-reactive protein concentration, in UC patients [8]. In
contrast, TIMP-2-mRNA levels remained unchanged and
no remarkable expression of TIMP-2 was observed in
inflamed mucosa of IBD patients [6,7]. To our knowledge,
no data regarding TIMP-4 in IBD have been previously
presented. On the other hand, the assessment of serum
TIMPs levels has not been performed to date in IBD
patients. The aim of the present study was to evaluate
serum levels of TIMPs -1, -2 and -4 in IBD patients and to
examine possible correlations with known inflammatory




One hundred and five consecutive IBD patients followed
up at the Department of Gastroenterology of the Univer-
sity Hospital of Larissa, in Thessaly, participated in this
study. Details on the clinical characteristics of the patients
included in the study are shown in table 1. All patients
had a definitive diagnosis UC or CD confirmed by clini-
cal, endoscopic, radiological and histological work-up.
Disease activity in CD patients was determined by the
Crohn's Disease Activity Index (CDAI) [9]. The cut-off
point for active disease was a score greater than 150. Dis-
ease activity in patients with UC was assessed by the Clin-
ical Colitis Activity Index (CCAI) [10]. A score greater than
4 on a scale of 0–16 was required for the disease to be con-
sidered active. Evaluation of disease activity was per-
formed at the time of serum collection. These patients
were compared with the control group, which consisted of
50 healthy blood donors (healthy controls, HC), 33 of
them were men, with a mean age (± SD) of 42.6 (± 9.8)
years. Apart from routine laboratory parameters, serum
amyloid A (SAA) and C reactive protein (CRP) were deter-
mined in all patients. Informed consent was obtained
from all patients. Patients with myeloproliferative disor-
ders, malignancies, or autoimmune diseases were
excluded from the study.
Laboratory tests
Blood samples were collected in serum separator tubes
and were centrifuged for 15 min at 1000 × g, right after a
30-minute clotting period had elapsed. All serum samples
were stored at -25°C until assayed. As far as the quantita-
tive serum determination of TIMP-1, TIMP-2 and TIMP-4
is concerned, commercially available solid phase enzyme-
linked immunosorbent assay (ELISA) kits (R&D Systems,
Abingdon, UK) were used. The minimum detectable
doses of TIMP-1, TIMP-2 and TIMP-4 were 0.08 ng/mL,
0.011 ng/mL and 4.91 pg/mL respectively. The intra- and
inter-assay coefficient variations for TIMP-1, TIMP-2 and
TIMP-4 were below 5%, 4.4% and 5.6% and below 4.9%,
7.3% and 9.2% respectively (n = 20 and n = 40 respec-
tively). All samples were assayed in duplicate.
Serum CRP and SAA measurements were performed by
immunonephelometry with the Behring Nephelometer
Analyzer II (BNII), using the N High Sensitivity kit and the
N Latex SAA kit (Dade Behring Gmbh, Germany), respec-
tively. The appropriate control and standard sera were
provided by the same company, and used according to the
manufacturer's instructions.BMC Gastroenterology 2008, 8:55 http://www.biomedcentral.com/1471-230X/8/55
Page 3 of 8
(page number not for citation purposes)
Statistical analysis
All results are expressed as mean ± SEM. Comparisons
between two groups were made by the Mann-Whitney U
test. A linear regression or a Spearman r-test was used to
assess correlation. All analyses were two-tailed and con-
ducted using the computer-based statistic software pro-
gram SPSS 15.0 for Windows. A level of p < 0.05 was
considered statistically significant.
Results
TIMPs serum levels (Figure 1; Figure 2; Figure 3)
Mean ± SEM serum TIMP-1 levels were 414.9 ± 17.6 ng/
mL (median: 385.8, range: 70.3–749.9) in UC patients,
446.1 ± 22.8 ng/mL (median: 414.4, range: 9.0–782.1) in
CD patients and 296.5 ± 20.6 ng/mL (median: 308.8,
range: 63.1–552.0) in HC, (Figure 1). UC and CD patients
had significantly higher serum TIMP-1 levels compared to
HC (p < 0.0001 in both groups). No statistically signifi-
cant difference was evident between UC and CD patients.
The mean serum TIMP-1 levels were significantly higher
in patients with active IBD (450.5 ng/mL) as compared
with patients with inactive disease (417.3 ng/mL, p =
0.03, Figure 2). Moreover, mean serum TIMP-1 levels
proved to be significantly higher in IBD males (448.9 ng/
mL), compared to IBD females (441.6 ng/mL, p = 0.01).
Male gender was associated in all groups, HC included,
with significantly higher mean serum TIMP-1 levels
(399.8 ng/mL) compared to female gender (368.5 ng/mL,
p = 0.04).
Mean (± SEM) serum TIMP-2 levels were 62.3 ± 2.3 ng/mL
(median: 60.4, range: 33.5–112.0) in UC patients, 61.9 ±
2.4 ng/mL (median: 60.9, range: 0.6–106.0) in CD
patients and 61.8 ± 4.5 ng/mL (median: 57.7, range: 2.0–
187.7) in HC. No statistically significant difference was
recorded between IBD patients and HC and this was also
the case for patients with active and inactive disease (p >
0.05 in all cases).
Mean (± SEM) serum TIMP-4 levels were 1761.2 ± 67.7
pg/mL (median: 1658.1, range: 1089.3–2957.8) in UC
patients, 1708.1 ± 73.4 pg/mL (median: 1655.1, range:
965.1–3605.9) in CD patients and 5573.4 ± 1246.3 pg/
mL (median: 1364.4, range: 336.4–41.752.1) in HC, (Fig-
Table 1: Clinical characteristic of the patients with inflammatory bowel disease
UC CD
Patients no 53 52
Mean age ± SD (range), years 49.8 ± 13.9 (20–79) 36.6 ± 13.6 (17–69)
Mean duration of disease ± SD (range), months 85.9 ± 81.8 (1–348) 72.4 ± 68.6 (1–388)
Male 30 21
Female 23 31
Current smokers 5 32
Ex smokers 20 2













Active disease 22 17
Inactive disease 31 35




Enemas (5-ASA and/or steroids) 27 5
Immunosuppressive agents 13 21
Metronidazole 11 28
Infliximab 4 15
Parenteral nutrition 2 1
*Some patients received > 1 drug.BMC Gastroenterology 2008, 8:55 http://www.biomedcentral.com/1471-230X/8/55
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ure 3). UC and CD patients showed significantly lower
serum TIMP-4 levels compared to HC (p = 0.008 and p =
0.02 respectively). The difference observed in TIMP-4 lev-
els between UC and CD patients, as well as between
patients with active and inactive disease proved to be non-
significant. There was a trend toward lower mean serum
TIMP-4 levels in males with IBD (1650.7 pg/mL), as com-
pared with females (1797.2 pg/mL), but this difference
was not statistically significant. Interestingly males,
including HC had significantly lower mean serum TIMP-
4 levels (2772.9 pg/mL), as compared with females
(3299.0 pg/mL, p = 0.01).
Analyses of other subgroups did not reveal any statistically
significant difference in the serum levels of TIMP-1, TIMP-
2 and TIMP-4 when ever and never smokers, and patients
with or without extraintestinal manifestations were com-
pared (p > 0.05 in all cases). Treatment with 5-ASA alone
or with additional corticosteroids, infliximab or immuno-
suppressive agents, did not appear to influence TIMPs'
serum levels. Moreover, TIMPs' serum levels did not vary
significantly among the subgroups in which patients
where classified with regard to disease location and
behavior of CD, or the extent of UC.
TIMP-1/TIMP-4 ratio
The mean ± SEM ratio between TIMP-1 and TIMP-4 levels
was 0.25 ± 0.01 ng/mL (median: 0.24, range: 0.03–0.47)
in UC patients, 0.28 ± 0.02 ng/mL (median: 0.25, range:
0.005–0.66) in CD patients and 0.22 ± 0.03 ng/mL
(median: 0.22, range: 0.003–1.00) in HC. CD patients (p
= 0.036) but not UC (p = 0.174) had significantly higher
TIMP1/TIMP-4 ratio compared to HC group. No signifi-
cant difference was found between UC and CD patients (p
Bar graph showing TIMP-1 levels in UC, CD patients and HC and the statistical significance of mean differences Figure 1
Bar graph showing TIMP-1 levels in UC, CD patients and HC and the statistical significance of mean differ-
ences.BMC Gastroenterology 2008, 8:55 http://www.biomedcentral.com/1471-230X/8/55
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= 0.247). Also, the aforementioned ratio was not different
between patients with active IBD as compared with
patients with inactive disease (p = 0.528).
SAA and CRP levels
Patients with active IBD had statistically significant higher
SAA levels, (8.66 ± 3.84, range: 0.2–84.4), as compared
with the patients with inactive disease (6.25 ± 1.70, range:
0.10–58.80, p = 0.001). Similarly, patients with active IBD
had statistically significant higher CRP levels, (2.27 ±
1.20, range: 0.75–31.15), compared to patients with inac-
tive disease (1.10 ± 0.30, range: 0.00–19.20, p = 0.002).
Correlation studies
The CRP levels were found to be significantly correlated
with the levels of TIMP-1 (r = 0.247, p = 0.01) and TIMP-
4 (r = 0.217, p = 0.03). Likewise, SAA levels were found to
be significantly correlated with the levels of TIMP-1 (r =
0.264, p = 0.008) and TIMP-4 (r = 0.212, p = 0.03). A sta-
tistically significant correlation between TIMP-1 and
TIMP-4 levels (r = 0.221, p = 0.02) was also observed. No
correlations were evident between TIMP-1 or TIMP-4
serum levels and the age of patients or the duration of dis-
ease.
Discussion
Our study provides new data on the tissue remodeling
process in IBD with regard to serum TIMPs levels. We con-
firmed an increased production of TIMP-1 in IBD
patients, especially in active disease and showed that this
increase correlated with the production of the well-known
inflammatory markers CRP and SAA. On the other hand,
a decreased production of TIMP-4 was detected in these
patients, which was independent of disease activity along
with a strong correlation between TIMP-4 levels and the
studied inflammatory markers. What seemed to be of par-
Bar graph showing TIMP-1 levels in patients with active and inactive IBD Figure 2
Bar graph showing TIMP-1 levels in patients with active and inactive IBD.BMC Gastroenterology 2008, 8:55 http://www.biomedcentral.com/1471-230X/8/55
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ticular interest was also the observation that males in
comparison with females, tend to show an increased pro-
duction of TIMP-1, accompanied by a decreased produc-
tion of serum TIMP-4.
It has been shown that the uncontrolled and sustained
inflammatory cascade, observed in IBD, gives rise to the
production of MMPs and TIMPs which in turn can induce
tissue degradation and lesion development [1,2]. We
agree that the determination of serum MMP levels would
add to the impact of this study. Unfortunately this was not
included in the initial study design. The sera from these
150 patients are not available anymore, as they have been
utilized for other determinations. On the other hand, it
would be biased to obtain new sera because the inflam-
matory status (activity) of these patients has changed.
An increased production of TIMP-1 at the mucosa and
plasma of IBD patients has been previously described [5-
8]. It has also been demonstrated that in IBD, TIMP-1 is
expressed by inflammatory cells, fibroblasts and vascular
smooth muscle cells most prominently in actively
inflamed areas in ulcer bases [7]. In an ex vivo study using
tissue cultures of intestinal biopsies from IBD patients,
TIMP-1 was detected in significant titers in inflamed
mucosa of both CD and UC specimens, in contrast with
uninflamed mucosa [5]. In the above-mentioned study,
TIMP-1 showed strong correlation with proinflammatory
cytokines IL-6, IL-1β and IL-10. In another study, an
increased expression of TIMP-1 mRNA in inflamed and
especially ulcerated colon mucosa of IBD patients was evi-
dent [6].
Bar graph showing TIMP-4 levels in UC, CD patients and HC and the statistical significance of mean differences Figure 3
Bar graph showing TIMP-4 levels in UC, CD patients and HC and the statistical significance of mean differ-
ences.BMC Gastroenterology 2008, 8:55 http://www.biomedcentral.com/1471-230X/8/55
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Increased levels of TIMP-1 have also been associated with
the presence of fibrotic strictures in CD [11]. It is well
known that, TIMPs are important markers of fibrosis. In
addition, CD and especially its stenotic form are charac-
terized by increased fibrosis. It was thus expected to find a
more pronounced increase in TIMP-1 levels, in these sub-
groups. In our study, a trend towards higher TIMP-1 levels
was observed in CD compared with UC patients which
was not statistically significant. This could be attributed to
the rather small number of patients which did not allow
reliable subgroup analysis. In a recent study, TIMP-1
plasma levels in UC patients were found to correlate pos-
itively with scored endoscopic degree of mucosal injury,
disease activity indices, clinical activity indices and CRP
concentration, thus implying that TIMP-1 plasma concen-
tration may be a possible biomarker of disease activity [8].
External stimuli such as growth factors, phorbol esters and
cytokines (IL-6, IL-1 and IL-1b) are all well-known triggers
of TIMP-1 expression in various cell types [4,12]. Erythro-
poietin (EPO) a hormone that also serves as a promoter of
TIMP-1 secretion, is increased in IBD patients, as we have
demonstrated in a previous study [13]. Thus, it is possible
that EPO and TIMP-1 act in a collaborative manner and
play a key role not only in the erythroid cell physiology
but also in several pathophysiological events in IBD.
No statistically significant difference in TIMP-2 levels was
recorded between IBD patients and HC, in our study.
TIMP-2 mRNA levels measured by polymerase chain reac-
tion (PCR) in biopsies from IBD patients, remained
unchanged in inflamed and uninflamed mucosa, in the
study of von Lampe et al [6]. Finally, no remarkable
expression of TIMP-2 was observed in inflamed mucosa of
IBD patients, in an immunohistochemical study by Ari-
hiro et al [7]. However, it is not safe to draw any conclu-
sions based solely on these data thus, this subject requires
further studies.
One major finding presented in this study is that TIMP-4
serum levels are decreased in IBD patients, irrespective of
disease activity. When interpreting this result many con-
siderations need to be taken into account. TIMP-4, the
newest member of TIMPs, is a tissue-specific regulator of
EMC remodeling, promoting inhibition of the MMP-2
activation [3]. On the other hand, MMP-2 activity in IBD
patients has been shown to be rather excessive and it
could be held accountable for TIMP-4 consumption
which in turn could result in lower TIMP-4 levels. The
enhanced MMP-2 activity in IBD may be of significant
importance, as it is a key player in proper wound healing,
angiogenesis and re-epithelization, as well as in the regu-
lation of epithelial barrier function of the intestine [1,2].
It has also been suggested that the increased TIMP-4
expression in normal heart tissue could explain why myo-
cardial tumors are so rare [14]. On the other hand, there
is evidence that low TIMP-4 levels result in an anti-apop-
totic effect [15]. These reports, taken together with the
data of the present study, may support the importance of
low TIMP-4 levels in IBD-related tumorigenesis. Addition-
ally, TIMP-4 has been shown to inhibit platelet aggrega-
tion, thus implying TIMP-4 involvement in the regulation
of platelet aggregation and recruitment [16]. These plate-
let aggregation responses proved to be enhanced in IBD
patients, even in inactive disease [17]. These findings sug-
gest that, the decreased TIMP-4 serum levels observed in
IBD patients, even those with inactive disease, have an
aggravating influence on the platelet aggregation in IBD.
To confirm these speculations, further studies are neces-
sary. In any case, the imbalance of TIMP-1 and TIMP-4
serum levels observed herein, may reflect the paradoxical
effects of these inhibitors, which may act as either pro-
moters or suppressors in many important pathophysio-
logical processes involved in inflammation and wound
healing in IBD.
We have also showed that, gender has an influence on
TIMP-1 and TIMP-4 serum levels. This gender-related dif-
ference may prove interesting but, how this is controlled
is the subject of many differing lines of research. The
involvement of TIMP-1 in steroidogenesis was first evi-
denced in Leyding cells and ovarian granulose cells and
led to the conclusion that it could affect germ cell devel-
opment, by regulating steroid concentrations in both
males and females [18]. Moreover, it has been shown that
TIMP-1 is not a prerequisite for overall germ cell develop-
ment and that it could be substituted by one of the other
TIMPs [19]. According to our results, TIMP-4 could be a
candidate for such an action. In a recent study with a rela-
tively small sample size, no significant difference in TIMP-
1 plasma levels between females and males was recorded
[20]. Given the fact however, that only a few TIMP-related
studies with focus on gender have been published, future
studies are required so that our findings could be clarified.
Conclusion
In summary, our data may reflect the continuous matrix
turnover occurring in IBD, a process strongly associated
with an imbalance of TIMP-1 and TIMP-4 serum levels.
The increase of TIMP-1 serum levels in active disease and
their significant correlation with the production of known
inflammatory markers such as CRP and SAA, indicate that
TIMP-1 levels could be used not only for diagnostic pur-
poses but also for the assessment of activity in IBD. These
findings bring into question the potential role of TIMPs in
the pathogenesis, activity and therapy of IBD, thus
emphasizing the need for further studies on this subject.
Perhaps, in the future, the modulation of MMP and TIMP
activities as well as ECM turnover may become part of a
more rational, mechanism-based therapeutic manipula-
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